Carlo Riccardo Rossi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1377422/publications.pdf

Version: 2024-02-01

219 papers	9,260 citations	44069 48 h-index	51608 86 g-index
228 all docs	228 docs citations	228 times ranked	10327 citing authors

#	Article	IF	Citations
1	Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2010, 102, 493-501.	6.3	487
2	Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience. Annals of Surgical Oncology, 2000, 7, 469-474.	1.5	318
3	IL4RÎ±+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients. Journal of Immunology, 2009, 182, 6562-6568.	0.8	287
4	Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo, 2014, 28, 1005-11.	1.3	269
5	Tumor necrosis factor, cancer and anticancer therapy. Cytokine and Growth Factor Reviews, 2005, 16, 35-53.	7.2	263
6	Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institutionâ€™s Experience with 52 Patients. Annals of Surgical Oncology, 2009, 16, 191-199.	1.5	256
7	The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine and Growth Factor Reviews, 2004, 15, 61-76.	7.2	214
8	Incidence of soft tissue sarcoma and beyond. Cancer, 2012, 118, 5339-5348.	4.1	210
9	The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis. Clinical Cancer Research, 2006, 12, 4605-4613.	7.0	197
10	Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Medical and Biological Engineering and Computing, 2012, 50, 1213-1225.	2.8	188
11	Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Annals of Oncology, 2012, 23, 2442-2449.	1.2	179
12	Circulating tumor cells: the â€˜leukemic phaseâ€™ of solid cancers. Trends in Molecular Medicine, 2006, 12, 130-139.	6.7	177
13	Quantitative real-time PCR: a powerful ally in cancer research. Trends in Molecular Medicine, 2003, 9, 189-195.	6.7	174
14	Gastrointestinal stromal tumors: From a surgical to a molecular approach. International Journal of Cancer, 2003, 107, 171-176.	5.1	136
15	Systemic treatments for metastatic cutaneous melanoma. The Cochrane Library, 2020, 2020, CD011123.	2.8	136
16	Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Intraoperative Chemotherapy for Peritoneal Carcinomatosis Arising From Colon Adenocarcinoma. Annals of Surgical Oncology, 2003, 10, 508-513.	1.5	132
17	Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISMâ€“IMI). Annals of Surgical Oncology, 2009, 16, 2018-2027.	1.5	121
18	Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O.. European Journal of Surgical Oncology, 2011, 37, 148-154.	1.0	120

#	Article	IF	Citations
19	The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. Journal of Surgical Oncology, 2003, 83, 80-84.	1.7	107
20	Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. Cancer, 2004, 100, 1943-1950.	4.1	103
21	Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget, 2016, 7, 1168-1184.	1.8	103
22	Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiology and Oncology, 2016, 50, 1-13.	1.7	101
23	IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes and Immunity, 2004, 5, 621-630.	4.1	99
24	Evaluation of Lymph Node Perfusion Using Continuous Mode Harmonic Ultrasonography With a Second-Generation Contrast Agent. Journal of Ultrasound in Medicine, 2004, 23, 829-836.	1.7	98
25	Sentinel Lymph Node Molecular Ultrastaging in Patients With Melanoma: A Systematic Review and Meta-Analysis of Prognosis. Journal of Clinical Oncology, 2007, 25, 1588-1595.	1.6	96
26	The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study. Breast Cancer Research and Treatment, 2012, 134, 1169-1178.	2.5	96
27	A gene expression signature associated with survival in metastatic melanoma. Journal of Translational Medicine, 2006, 4, 50.	4.4	93
28	Electrochemotherapy for disseminated superficial metastases from malignant melanoma. British Journal of Surgery, 2012, 99, 821-830.	0.3	89
29	Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT. British Journal of Dermatology, 2017, 176, 1475-1485.	1.5	84
30	Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. European Journal of Cancer, 2005, 41, 118-125.	2.8	83
31	Soft tissue limb sarcomas. , 1999, 86, 1742-1749.		79
32	Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer, 1994, 73, 2140-2146.	4.1	78
33	Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis. Cancer, 2002, 94, 492-499.	4.1	77
34	Glutathione Transferases as Targets for Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 763-777.	1.7	72
35	Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies. BMC Medicine, 2018, 16, 20.	5.5	71
36	Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-Î± and Melphalan for Bulky In-Transit Melanoma Metastases. Annals of Surgical Oncology, 2004, 11, 173-177.	1.5	69

#	Article	IF	Citations
37	Eruptive melanocytic nevi in patients with renal allografts: Report of 10 cases with dermoscopic findings. Journal of the American Academy of Dermatology, 2003, 49, 1020-1022.	1.2	65
38	Factors Predictive of Nonsentinel Lymph Node Involvement and Clinical Outcome in Melanoma Patients With Metastatic Sentinel Lymph Node. Annals of Surgical Oncology, 2008, 15, 1202-1210.	1.5	64
39	Ultrasonographic evaluation of superficial lymph node metastases in melanoma. European Journal of Radiology, 1997, 24, 216-221.	2.6	61
40	Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). Annals of Oncology, 2013, 24, 1685-1691.	1.2	61
41	Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches. Cancer Treatment Reviews, 2006, 32, 9-27.	7.7	59
42	The impact of ultrasound scanning in the staging and follow-up of patients with clinical stage i cutaneous melanoma. European Journal of Cancer, 1997, 33, 200-203.	2.8	57
43	Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. BMC Health Services Research, 2012, 12, 82.	2.2	57
44	Impact of Molecular Analysis on the Final Sarcoma Diagnosis. American Journal of Surgical Pathology, 2013, 37, 1259-1268.	3.7	55
45	Early (sentinel lymph node biopsyâ€guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases. Cancer, 2010, 116, 1201-1209.	4.1	54
46	The Wnt/Î²-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target. Molecular and Cellular Therapies, 2015, 3, 1.	0.2	54
47	Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. International Journal of Cancer, 2004, 111, 741-745.	5.1	53
48	Electrochemotherapy in non-melanoma head and neck cancers: a retrospective analysis of the treated cases. British Journal of Oral and Maxillofacial Surgery, 2014, 52, 957-964.	0.8	50
49	Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. British Journal of Surgery, 2012, 99, 1396-1405.	0.3	49
50	Nonsentinel Lymph Node Status in Patients With Cutaneous Melanoma: Results From a Multi-Institution Prognostic Study. Journal of Clinical Oncology, 2014, 32, 935-941.	1.6	49
51	Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents. Cancer Chemotherapy and Pharmacology, 2000, 46, 517-522.	2.3	48
52	Isolated limb perfusion in locally advanced cutaneous melanoma. Seminars in Oncology, 2002, 29, 400-409.	2.2	48
53	Electrochemotherapy Treatment of Locally Advanced and Metastatic Soft Tissue Sarcomas: Results of a Nonâ€Comparative Phase II Study. World Journal of Surgery, 2014, 38, 813-822.	1.6	48
54	Cutaneous Melanoma in Children and Adolescents: The Italian Rare Tumors in Pediatric Age Project Experience. Journal of Pediatrics, 2014, 164, 376-382.e2.	1.8	47

#	Article	IF	Citations
55	Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. Cancer Treatment Reviews, 2017, 54, 34-42.	7.7	46
56	Gastrointestinal stromal tumors: report of an audit and review of the literature. European Journal of Cancer Prevention, 2009, 18, 106-116.	1.3	45
57	Treatment of metastatic melanoma with electrochemotherapy. Journal of Surgical Oncology, 2014, 109, 301-307.	1.7	45
58	Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study. Annals of Surgical Oncology, 2018, 25, 271-279.	1.5	44
59	Bleomycin electrochemotherapy in elderly metastatic breast cancer patients: clinical outcome and management considerations. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1557-1565.	2.5	43
60	Large and Dissimilar Repertoire of Melan-A/MART-1-Specific CTL in Metastatic Lesions and Blood of a Melanoma Patient. Journal of Immunology, 2002, 169, 4017-4024.	0.8	42
61	Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment. Journal of Immunological Methods, 2003, 280, 1-11.	1.4	42
62	Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer, 2009, 9, 352.	2.6	42
63	Surgeonsâ€™ Opinions on Lymphadenectomy in Melanoma Patients with Positive Sentinel Nodes: A Worldwide Web-Based Survey. Annals of Surgical Oncology, 2012, 19, 4322-4329.	1.5	42
64	Number of Excised Lymph Nodes as a Quality Assurance Measure for Lymphadenectomy in Melanoma. JAMA Surgery, 2014, 149, 700.	4.3	42
65	Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor Î± and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas. Annals of Surgical Oncology, 2005, 12, 398-405.	1.5	41
66	A novel10B-enriched carboranyl-containing phthalocyanine as a radio- and photo-sensitising agent for boron neutron capture therapy and photodynamic therapy of tumours: in vitro and in vivo studies. Photochemical and Photobiological Sciences, 2006, 5, 39-50.	2.9	41
67	Automated Quantitative Evaluation of Lymph Node Perfusion on Contrast-Enhanced Sonography. American Journal of Roentgenology, 2007, 188, 977-983.	2.2	41
68	Sentinel node biopsy in pediatric soft tissue sarcomas of extremities. Pediatric Blood and Cancer, 2009, 52, 51-54.	1.5	41
69	Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surgical Oncology Clinics of North America, 2003, 12, 781-794.	1.5	39
70	Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. European Journal of Surgical Oncology, 2001, 27, 125-134.	1.0	38
71	Part II: Vaccines for haematological malignant disorders. Lancet Oncology, The, 2004, 5, 727-737.	10.7	37
72	DNA Array-Based Gene Profiling. Annals of Surgery, 2005, 241, 16-26.	4.2	37

#	Article	IF	Citations
73	The consensus statement on the locoregional treatment of abdominal sarcomatosis. Journal of Surgical Oncology, 2008, 98, 291-294.	1.7	36
74	N-Ratio: a Novel Independent Prognostic Factor for Patients with Stage-III Cutaneous Melanoma. Annals of Surgical Oncology, 2008, 15, 310-315.	1.5	36
75	Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases. Annals of Surgical Oncology, 2010, 17, 3000-3007.	1.5	35
76	The Role of Laparoscopy in Peritoneal Surface Malignancies Selected for Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology, 2012, 19, 3737-3744.	1.5	35
77	Utility of electrochemotherapy in melanoma treatment. Current Opinion in Oncology, 2012, 24, 155-161.	2.4	34
78	The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis. Annals of Oncology, 2014, 25, 240-246.	1.2	34
79	Evaluation of the Electroporation Efficiency of a Grid Electrode for Electrochemotherapy. Technology in Cancer Research and Treatment, 2016, 15, 296-307.	1.9	33
80	Early detection of melanoma: an educational campaign in Padova, Italy. Melanoma Research, 2000, 10, 181-187.	1.2	32
81	Cancer vaccine development: on the way to break immune tolerance to malignant cells. Experimental Cell Research, 2004, 299, 267-278.	2.6	32
82	Tumour-localizing and -photosensitising properties of meso-tetra(4-nido-carboranylphenyl)porphyrin (H2TCP). Journal of Photochemistry and Photobiology B: Biology, 2007, 89, 131-138.	3.8	32
83	Colorectal cancer vaccines: Principles, results, and perspectives. Gastroenterology, 2004, 127, 1821-1837.	1.3	31
84	The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI). Journal of Nuclear Medicine, 2006, 47, 234-41.	5.0	31
85	Protein profiles in sera of patients with malignant cutaneous melanoma. Rapid Communications in Mass Spectrometry, 2000, 14, 1149-1154.	1.5	30
86	A European project on incidence, treatment, and outcome of sarcoma. BMC Public Health, 2010, 10, 188.	2.9	30
87	Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multiâ€institutional retrospective study. Journal of Surgical Oncology, 2016, 114, 246-253.	1.7	30
88	Imaging of softâ€tissue tumors. Journal of Magnetic Resonance Imaging, 2013, 37, 791-804.	3.4	29
89	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714.	1.8	29
90	Electrical resistance of human soft tissue sarcomas: an ex vivo study on surgical specimens. Medical and Biological Engineering and Computing, 2016, 54, 773-787.	2.8	29

#	Article	IF	Citations
91	Management of cutaneous melanoma M0: state of the art and trends. European Journal of Cancer, 1997, 33, 2302-2312.	2.8	28
92	Sentinel Node Status Prediction by Four Statistical Models. Annals of Surgery, 2009, 250, 964-969.	4.2	28
93	IncreasedTIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-? to patients with soft tissue limb sarcoma. International Journal of Cancer, 2003, 107, 317-322.	5.1	27
94	CA 19-9 determination in gastric justice: Role in identifying gastric cancer and high risk patients. European Journal of Cancer & Clinical Oncology, 1988, 24, 923-927.	0.7	26
95	Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience. International Journal of Hyperthermia, 2016, 32, 165-172.	2.5	26
96	Magnetic Resonance Imaging Assessment of Lipomatous Soft-tissue Tumors. In Vivo, 2017, 31, 387-395.	1.3	26
97	Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. American Journal of Surgery, 2002, 183, 28-36.	1.8	25
98	Video endoscopic inguinal lymphadenectomy for lymph node metastasis from solid tumors. European Journal of Surgical Oncology, 2015, 41, 274-281.	1.0	25
99	Sentinel node biopsy and ultrasound scanning in cutaneous melanoma. European Journal of Cancer, 2000, 36, 895-900.	2.8	24
100	Molecular oncology in the post-genomic era: the challenge of proteomics. Trends in Molecular Medicine, 2004, 10, 24-32.	6.7	24
101	Support Vector Machine Learning Model for the Prediction of Sentinel Node Status in Patients With Cutaneous Melanoma. Annals of Surgical Oncology, 2006, 13, 1113-1122.	1.5	24
102	Discrepant alterations in main candidate genes among multiple primary melanomas. Journal of Translational Medicine, 2014, 12, 117.	4.4	24
103	Limb-sparing treatment for soft tissue sarcomas: Influence of prognostic factors. , 1996, 63, 3-8.		23
104	The application of hyperthermia in regional chemotherapy. , 1998, 14, 215-223.		23
105	TNFÎ±-Based Isolated Perfusion for Limb-Threatening Soft Tissue Sarcomas: State of the Art and Future Trends. Journal of Immunotherapy, 2003, 26, 291-300.	2.4	23
106	Maximizing the clinical usefulness of a nomogram to select patients candidate to sentinel node biopsy for cutaneous melanoma. European Journal of Surgical Oncology, 2011, 37, 675-680.	1.0	23
107	Validation of the prognostic value ofÂlymph node ratio in patients withÂcutaneous melanoma: A population-based study of 8,177 cases. Surgery, 2011, 150, 83-90.	1.9	22
108	Subareolar injection for sentinel lymph node location in breast cancer. European Journal of Surgical Oncology, 2002, 28, 701-704.	1.0	21

#	Article	IF	Citations
109	Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma. Melanoma Research, 2003, 13, 51-58.	1.2	21
110	Induction of Endothelial Nitric Oxide Synthase Expression by Melanoma Sensitizes Endothelial Cells to Tumor Necrosis Factor-Driven Cytotoxicity. Clinical Cancer Research, 2004, 10, 6879-6886.	7.0	21
111	Surgical Treatment of Melanoma: A Survey of Italian Hospitals. Dermatology, 2013, 226, 28-31.	2.1	21
112	Principles of Gene Microarray Data Analysis. , 2007, 593, 19-30.		21
113	Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA. Nuclear Medicine Communications, 2004, 25, 61-66.	1.1	20
114	Cyto-reductive Surgery combined with Hyperthermic Intra-Peritoneal Chemotherapy for Peritoneal Surface Malignancies: Current treatment and results. Cancer Treatment Reviews, 2012, 38, 258-268.	7.7	20
115	Optimal Needle Positioning for Electrochemotherapy: A Constrained Multiobjective Strategy. IEEE Transactions on Magnetics, 2013, 49, 2141-2144.	2.1	20
116	Core needle biopsy of soft tissue tumors, CEUS vs US guided: a pilot study. Journal of Ultrasound, 2015, 18, 335-342.	1.3	20
117	Standardization and quality control of surgical treatment ofÂcutaneous melanoma: Looking for consensus ofÂtheÂItalian Melanoma Intergroup. European Journal of Surgical Oncology, 2015, 41, 148-156.	1.0	20
118	A prototype of a flexible grid electrode to treat widespread superficial tumors by means of Electrochemotherapy. Radiology and Oncology, 2016, 50, 49-57.	1.7	20
119	Literature search on risk factors for sarcoma: PubMed and Google Scholar may be complementary sources. BMC Research Notes, 2010, 3, 131.	1.4	19
120	Histopathological characteristics of subsequent melanomas in patients with multiple primary melanomas. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 58-64.	2.4	19
121	In vivo characterization of a doxorubicin resistant B16 melanoma cell line. British Journal of Cancer, 1986, 54, 223-233.	6.4	18
122	Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. Biochimica Et Biophysica Acta: Reviews on Cancer, 2003, 1653, 61-71.	7.4	18
123	Targeted Therapy Database (TTD): A Model to Match Patient's Molecular Profile with Current Knowledge on Cancer Biology. PLoS ONE, 2010, 5, e11965.	2.5	18
124	Lymph-Node Ratio in Patients with Cutaneous Melanoma: A Multi-Institution Prognostic Study. Annals of Surgical Oncology, 2015, 22, 2127-2134.	1.5	18
125	Videoscopic ilioinguinal lymphadenectomy for groin lymph node metastases from melanoma. British Journal of Surgery, 2016, 103, 1026-1032.	0.3	18
126	Influence of age and menopausal status on pathologic and biologic features of breast cancer. Breast, 2000, 9, 320-328.	2.2	17

#	Article	IF	Citations
127	Stop-flow technique for loco-regional delivery of antiblastic agents: literature review and personal experience. European Journal of Surgical Oncology, 2002, 28, 544-553.	1.0	17
128	TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial. Annals of Surgical Oncology, 2008, 15, 1218-1223.	1.5	17
129	Measuring the quality of melanoma surgery â€“ Highlighting issues with standardization and quality assurance of care in surgical oncology. European Journal of Surgical Oncology, 2017, 43, 561-571.	1.0	17
130	Can sentinel node biopsy be safely omitted in thin melanoma? Risk factor analysis of 1272 multicenter prospective cases. European Journal of Surgical Oncology, 2019, 45, 820-824.	1.0	17
131	Proliferating cell nuclear antigen (PCNA) and recurrence in patients with cutaneous melanoma. Melanoma Research, 1994, 4, 207-211.	1.2	16
132	Neoadjuvant treatment with dabrafenib of unresectable localizations from occult melanoma. Melanoma Research, 2014, 24, 413-414.	1.2	16
133	Associations of clock genes polymorphisms with soft tissue sarcoma susceptibility and prognosis. Journal of Translational Medicine, 2018, 16, 338.	4.4	16
134	Is there a relationship between influenza vaccinations and risk of melanoma? A population-based case-control study. European Journal of Epidemiology, 2000, 16, 777-782.	5.7	14
135	The Melanoma Molecular Map Project. Melanoma Research, 2008, 18, 163-165.	1.2	14
136	The value of electrochemotherapy in the treatment of peristomal tumors. European Journal of Surgical Oncology, 2014, 40, 260-262.	1.0	14
137	Myoepithelioma of the soft tissue: A systematic review of clinical reports. European Journal of Surgical Oncology, 2019, 45, 1520-1526.	1.0	14
138	Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. Oncotarget, 2018, 9, 18607-18626.	1.8	14
139	Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study. Frontiers in Oncology, 2021, 11, 737399.	2.8	14
140	Multimodality treatment of extra-visceral soft tissue sarcomas M0 state of the art and trends. European Journal of Surgical Oncology, 1995, 21, 125-135.	1.0	13
141	Contrast-enhanced ultrasound findings in soft-tissue lesions: preliminary results. Journal of Ultrasound, 2013, 16, 21-27.	1.3	13
142	A new grid electrode for electrochemotherapy treatment of large skin tumors. IEEE Transactions on Dielectrics and Electrical Insulation, 2014, 21, 1424-1432.	2.9	13
143	Angiosarcoma on Lymphedema (Stewartâ€“Treves Syndrome): A 12-Year Follow-up after Isolated Limb Perfusion, Limb Infusion, and Electrochemotherapy. Journal of Vascular and Interventional Radiology, 2016, 27, 444-446.	0.5	13
144	Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers. Rapid Communications in Mass Spectrometry, 2003, 17, 1511-1515.	1.5	12

#	Article	IF	Citations
145	High-sensitivity power Doppler imaging of normal superficial lymph nodes. Journal of Clinical Ultrasound, 2004, 32, 273-276.	0.8	12
146	Primary great saphenous vein leiomyosarcoma: Report of a case. Surgery Today, 2008, 38, 161-162.	1.5	12
147	Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells. Anti-Cancer Drugs, 2015, 26, 284-292.	1.4	12
148	Prognostic Role of Multiple Lymphatic Basin Drainage in Sentinel Lymph Node-Negative Trunk Melanoma Patients: A Multicenter Study from the Italian Melanoma Intergroup. Annals of Surgical Oncology, 2016, 23, 1708-1715.	1.5	12
149	Soft tissue limb and trunk sarcomas: diagnosis, treatment and follow-up. Anticancer Research, 2014, 34, 5251-62.	1.1	12
150	Actual False-Negative Rate Prompts the Routine Use of Ultrasound Scan Before and After Sentinel Node Biopsy in Melanoma. Annals of Surgical Oncology, 2008, 15, 2976-2977.	1.5	11
151	Synthesis and Preliminary in Vitro Biological Evaluation of 4-[(4-Hydroxyphenyl)sulfanyl]but-3-en-2-one, a 4-Mercaptophenol Derivative Designed As a Novel Bifunctional Antimelanoma Agent. Journal of Medicinal Chemistry, 2009, 52, 4973-4976.	6.4	11
152	Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study. European Journal of Surgical Oncology, 2015, 41, 823-829.	1.0	11
153	Realâ€world data for direct stageâ€specific costs of melanoma healthcare. British Journal of Dermatology, 2020, 183, 171-172.	1.5	11
154	Recurrent retroperitoneal sarcomas: Clinical outcomes of surgical treatment and prognostic factors. European Journal of Surgical Oncology, 2021, 47, 1201-1206.	1.0	11
155	Doxorubicin Activity Is Enhanced by Hyperthermia in a Model of Ex Vivo Vascular Perfusion of Human Colon Carcinoma. World Journal of Surgery, 2003, 27, 640-646.	1.6	10
156	Strategies to enhance the anticancer potential of TNF. Frontiers in Bioscience - Landmark, 2008, 13, 3181.	3.0	10
157	Melanoma M (Zero): Diagnosis and Therapy. ISRN Dermatology, 2013, 2013, 1-10.	1.9	10
158	Long-term Survival of Patients With Invasive Ultra-thin Cutaneous Melanoma. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	1.0	10
159	Isolated limb perfusion for the management limb threatening soft tissue sarcomas: The role of histological type on clinical outcomes. European Journal of Surgical Oncology, 2017, 43, 401-406.	1.0	10
160	Sentinel node biopsy in breast cancer. Breast, 2000, 9, 139-143.	2.2	9
161	Sentinel node biopsy for breast cancer: is it already a standard of care? A survey of current practice in an Italian region. BMC Cancer, 2004, 4, 2.	2.6	9
162	Hypoxic Antiblastic Stop-Flow Perfusion: Clinical Outcome and Pharmacokinetic Findings. Journal of Chemotherapy, 2004, 16, 44-47.	1.5	9

#	Article	IF	Citations
163	Follow-Up of Melanoma: A Survey of Italian Hospitals. Dermatology, 2013, 226, 32-38.	2.1	9
164	Minimally invasive treatment of peristomal metastases from gastric cancer at an ileostomy site by electrochemotherapy. Radiology and Oncology, 2013, 47, 370-375.	1.7	9
165	Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool. BMC Health Services Research, 2014, 14, 537.	2.2	9
166	Effect of Electrode Distance in Grid Electrode: Numerical Models andIn VitroTests. Technology in Cancer Research and Treatment, 2018, 17, 153303381876449.	1.9	9
167	Adriamycin in hyperthermic perfusion for advanced limb sarcomas. Annals of Oncology, 1992, 3, S111-S113.	1.2	8
168	Growth rate and myofibroblast differentiation of desmoid fibroblast-like cells are modulated by TGF-Î² signaling. Histochemistry and Cell Biology, 2019, 151, 145-160.	1.7	8
169	Periostin and Epithelialâ€“Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma. Clinical Cancer Research, 2020, 26, 2921-2931.	7.0	8
170	Structured reporting using a shared indexed multilingual radiology lexicon. International Journal of Computer Assisted Radiology and Surgery, 2012, 7, 621-633.	2.8	7
171	A new grid electrode for electrochemotherapy treatment of large skin tumors. IEEE Transactions on Dielectrics and Electrical Insulation, 2014, 21, 1424-1432.	2.9	7
172	Pelvic lymph node status prediction in melanoma patients with inguinal lymph node metastasis. Melanoma Research, 2014, 24, 462-467.	1.2	7
173	Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. Journal of Cancer Research and Clinical Oncology, 2016, 142, 679-685.	2.5	7
174	Diagnostic value of contrast-enhanced CT combined with 18-FDG PET in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Abdominal Radiology, 2018, 43, 1094-1100.	2.1	7
175	Comparison between manual and automatic coding of medical record statistical cards at a university hospital. Medical Informatics = Medecine Et Informatique, 1993, 18, 53-59.	0.8	6
176	A Simplified Procedure for Continuous Intraoperative External Monitoring of Systemic Leakage during Isolated Limb Perfusion. Tumori, 2002, 88, S61-S63.	1.1	6
177	True versus Mild Hyperthermia during Isolated Hepatic Perfusion: Effects on Melphalan Pharmacokinetics and Liver Function. World Journal of Surgery, 2004, 28, 775-781.	1.6	6
178	Hyperthermic Isolated Liver Perfusion for Unresectable Liver Cancers: Pilot Study. Journal of Chemotherapy, 2004, 16, 37-39.	1.5	6
179	Search for Melanoma Markers in Plasma and Serum Samples. European Journal of Mass Spectrometry, 2005, 11, 353-360.	1.0	6
180	Correlation Between Melphalan Pharmacokinetics and Hepatic Toxicity Following Hyperthermic Isolated Liver Perfusion for Unresectable Metastatic Disease. Annals of Surgical Oncology, 2007, 14, 802-809.	1.5	6

#	Article	IF	Citations
181	Nuclear <scp>GSK</scp>â€3Î² segregation in desmoidâ€type fibromatosis. Histopathology, 2013, 62, 1098-1108.	2.9	6
182	Metastatic malignant soft tissue myoepithelioma: a case report showing complete response after locoregional and systemic therapy. Journal of Surgical Case Reports, 2013, 2013, rjt109-rjt109.	0.4	6
183	Calculating regional tissue volume for hyperthermic isolated limb perfusion: Four methods compared. European Journal of Surgical Oncology, 2016, 42, 1898-1905.	1.0	6
184	Multiple Lymph Node Basin Drainage in Trunk Melanoma Is Not Associated with Survival of Sentinel Lymph Node-Positive Patients. Dermatology, 2017, 233, 205-211.	2.1	6
185	Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. In Vivo, 2006, 20, 739-42.	1.3	6
186	Hyperthermic Isolated Perfusion with Low-Dose TNFÎ± and Doxorubicin in Patients with Locally Advanced Soft Tissue Limb Sarcomas. Journal of Chemotherapy, 2004, 16, 58-61.	1.5	5
187	Effect of Electrode Distance in Electrochemotherapy: From Numerical Model to in Vitro Tests. IFMBE Proceedings, 2016, , 167-170.	0.3	5
188	Laparoscopy in the abdominal staging of melanoma. European Journal of Cancer & Clinical Oncology, 1989, 25, 223-226.	0.7	4
189	Tumor Microenvironment: What have we Learned Studying the Immune Response in this Puzzling Battlefield?. Tumori, 2002, 88, 437-444.	1.1	4
190	Phase Iâ€“II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities. Melanoma Research, 2003, 13, 293-297.	1.2	4
191	Oncological outcome of videoscopic groin dissection for lymph node metastasis from melanoma. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 2576-2582.	2.4	4
192	Gender-specific associations between polymorphisms of the circadian gene RORA and cutaneous melanoma susceptibility. Journal of Translational Medicine, 2021, 19, 57.	4.4	4
193	Loco-regional recurrences of superficial soft tissue sarcomas and melanoma. European Radiology, 1992, 2, 180-183.	4.5	3
194	Quality assurance of lymphadenectomy for melanoma: Why and how?. European Journal of Surgical Oncology, 2016, 42, 1-2.	1.0	3
195	Quality assurance and sustainability of cancer care: A European networkÂis needed. European Journal of Surgical Oncology, 2018, 44, 383-385.	1.0	3
196	Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Peritoneal Metastases. Anticancer Research, 2018, 38, 5521-5524.	1.1	3
197	Quality assurance in melanoma care: The EU-MELACARE study. European Journal of Surgical Oncology, 2018, 44, 1773-1778.	1.0	3
198	Differences in direct costs of patients with stage I cutaneous melanoma: A real-world data analysis. European Journal of Surgical Oncology, 2020, 46, 976-981.	1.0	3

#	Article	IF	Citations
199	Quality management of cutaneous melanoma: impact on short-term outcomes and costs. European Journal of Dermatology, 2021, 31, 730-735.	0.6	3
200	Desmoid Fibromatosis of the Abdominal Wall: Surgical Resection and Reconstruction with Biological Matrix EgisÂ®. Case Reports in Oncology, 2017, 10, 205-211.	0.7	2
201	Cost-effectiveness of a melanoma screening programme using whole disease modelling. Journal of Medical Screening, 2020, 27, 157-167.	2.3	2
202	The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates. BMC Cancer, 2021, 21, 8.	2.6	2
203	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. Frontiers in Oncology, 2021, 11, 672797.	2.8	2
204	Direct Costs of Care for Adults with Soft Tissue Sarcomas: A Population-Based Study. Cancers, 2022, 14, 3109.	3.7	2
205	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 440.	1.1	1
206	Isolated Vascular Perfusion of Human Colon with Adenocarcinoma. World Journal of Surgery, 1999, 23, 197-201.	1.6	1
207	Sentinel Node Biopsy in Cutaneous Melanoma Patients: Technical and Clinical Aspects. Tumori, 2000, 86, 339-340.	1.1	1
208	Lymphadenectomy for Melanoma: Toward a Videoscopic Approach. Annals of Surgical Oncology, 2011, 18, 898-899.	1.5	1
209	Peritoneal Carcinomatosis from Colorectal Cancer. Updates in Surgery Series, 2015, , 271-294.	0.1	1
210	Locoregional Therapies and Surgical Oncology. , 2010, , 113-128.		1
211	Laparoscopic hyperthermic intraperitoneal chemotherapy for appendiceal tumors. Asian Journal of Endoscopic Surgery, 2020, 13, 614-617.	0.9	1
212	Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion. Melanoma Research, 2009, 19, 193-194.	1.2	0
213	9312 POSTER Health-Related Quality of Life Outcomes in Advanced Melanoma Patients After Palliative Treatment With Bleomycin-based Electrochemotherapy. European Journal of Cancer, 2011, 47, S656.	2.8	0
214	9302 ORAL Prognostic Significance of the Size, Site and Penetrative Depth of Sentinel Node Metastases in Melanoma Patients â€“ an International Multicenter Study. European Journal of Cancer, 2011, 47, S652-S653.	2.8	0
215	PCN76 Cost-Effectiveness Analysis of Compliance with Clinical Practice Guidelines in Sarcoma Treatment: An Economic Evaluation in Two European Regions. Value in Health, 2011, 14, A448.	0.3	0
216	Changing Perceptions of Lymphadenectomy and Sentinel Lymph Node Biopsy in Melanoma. , 2015, , .		0

#	Article	IF	Citations
217	Report from the second MIB (Melanoma Independent Board) Conference, 27â€“28 October 2014. Ecancermedicalscience, 2015, 9, 511.	1.1	0
218	Multimodal Treatment for Peritoneal Carcinomatosis of Digestive Origin. , 2002, , 265-279.		0
219	Surgical Technique and Indications for Radical Dissection: Head and Neck. Updates in Surgery Series, 2021, , 115-124.	0.1	0